Pharmacist-Driven Implementation of Fast Identification and Antimicrobial Susceptibility Testing Improves Outcomes for Patients with Gram-Negative Bacteremia and Candidemia.
AST
AXDX
bacteremia
fast identification
outcomes
patient outcomes
pharmacist
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
20 08 2020
20 08 2020
Historique:
received:
25
03
2020
accepted:
19
06
2020
pubmed:
1
7
2020
medline:
22
6
2021
entrez:
1
7
2020
Statut:
epublish
Résumé
Bloodstream infections (BSI) are associated with increased morbidity and mortality, especially when caused by Gram-negative or fungal pathogens. The objective of this study was to assess the impact of fast identification-antimicrobial susceptibility testing (ID/AST) with the Accelerate Pheno system (AXDX) from May 2018 to December 2018 on antibiotic therapy and patient outcomes. A pre-post quasiexperimental study of 200 patients (100 pre-AXDX implementation and 100 post-AXDX implementation) was conducted. The primary endpoints measured were time to first antibiotic intervention, time to most targeted antibiotic therapy, and 14-day hospital mortality. Secondary endpoints included hospital and intensive care unit (ICU) length of stay (LOS), antibiotic intensity score at 96 h, and 30-day readmission rates. Of 100 patients with Gram-negative bacteremia or candidemia in each cohort, 84 in the preimplementation group and 89 in the AXDX group met all inclusion criteria. The AXDX group had a decreased time to first antibiotic intervention (26.3 versus 8.0,
Identifiants
pubmed: 32601164
pii: AAC.00578-20
doi: 10.1128/AAC.00578-20
pmc: PMC7449197
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 Sheth et al.
Références
Infect Dis Rep. 2017 Mar 30;9(1):6839
pubmed: 28458798
Infect Control Hosp Epidemiol. 2016 Apr;37(4):425-32
pubmed: 26738993
BMC Infect Dis. 2015 Apr 25;15:197
pubmed: 25927970
Antimicrob Agents Chemother. 2005 Feb;49(2):760-6
pubmed: 15673761
Chest. 2000 Jul;118(1):146-55
pubmed: 10893372
Clin Infect Dis. 2020 Mar 17;70(7):1285-1293
pubmed: 31094414
J Clin Microbiol. 2017 Jul;55(7):2116-2126
pubmed: 28446572
Expert Rev Anti Infect Ther. 2005 Dec;3(6):915-22
pubmed: 16307504
Clin Infect Dis. 2013 Nov;57(9):1237-45
pubmed: 23899684
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Clin Microbiol Infect. 2018 Sep;24(9):944-955
pubmed: 29787889
Infect Control Hosp Epidemiol. 2014 Sep;35(9):1103-13
pubmed: 25111918
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Infect Dis. 2019 Jul 18;69(3):414-420
pubmed: 30312362
Pharmacotherapy. 2015 Mar;35(3):269-76
pubmed: 25809178
Clin Infect Dis. 2015 Oct 1;61(7):1071-80
pubmed: 26197846
J Antimicrob Chemother. 2017 Nov 1;72(11):3191-3198
pubmed: 28961942
Hosp Pharm. 2016 Nov;51(10):815-822
pubmed: 27928186